Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Down 2.2% – Should You Sell?

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) shares fell 2.2% during mid-day trading on Thursday . The stock traded as low as $7.80 and last traded at $8.02. 14,646 shares were traded during trading, a decline of 68% from the average session volume of 45,629 shares. The stock had previously closed at $8.20.

Analysts Set New Price Targets

Several equities research analysts have commented on the company. Stephens upgraded Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, May 1st. Oppenheimer raised their price objective on Sensei Biotherapeutics from $70.00 to $80.00 and gave the stock an “outperform” rating in a research report on Friday, March 28th. Finally, HC Wainwright upgraded Sensei Biotherapeutics to a “buy” rating and set a $100.00 price objective for the company in a research note on Monday, June 2nd.

Sensei Biotherapeutics Stock Down 2.2%

The firm has a market cap of $10.11 million, a price-to-earnings ratio of -0.35 and a beta of 0.27. The business has a 50 day moving average of $7.41 and a 200 day moving average of $8.36.

Sensei Biotherapeutics (NASDAQ:SNSE) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($5.40) earnings per share for the quarter, missing the consensus estimate of ($4.20) by ($1.20). Research analysts predict that Sensei Biotherapeutics, Inc. will post -1.17 earnings per share for the current year.

Institutional Investors Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. XTX Topco Ltd grew its holdings in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 351.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 62,903 shares of the company’s stock after acquiring an additional 48,977 shares during the quarter. XTX Topco Ltd owned about 0.25% of Sensei Biotherapeutics worth $31,000 as of its most recent SEC filing. Institutional investors and hedge funds own 10.50% of the company’s stock.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.